Prostate Cancer

>

Latest News

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.
3 Things You Should Know About Advancing mCRPC Care: Targeted Sequencing, Epigenetics, and Emerging Strategies

July 1st 2025

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.
Early Efficacy Seen With Gedatolisib-Based Therapies Prostate/Breast Cancers

June 30th 2025

225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.
Novel Targeted Therapy Shows Promise in PSMA-Positive Prostate Cancer

June 24th 2025

A retrospective study shows that [177Lu]Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.
Radioligand Therapy Retreatment Shows Promise in Metastatic CRPC

June 23rd 2025

The FDA did not expand the indication to include patients with non-homologous recombination-repair gene-mutated castration-resistant prostate cancer.
FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC

June 18th 2025

Video Series
Video Interviews
Podcasts
1 expert in this video
1 expert in this video
1 expert in this video
AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

More News